Company Quick10K Filing
Lixte Biotechnology Holdings
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 67 $54
10-Q 2019-11-08 Quarter: 2019-09-30
10-Q 2019-08-06 Quarter: 2019-06-30
10-Q 2019-05-09 Quarter: 2019-03-31
10-K 2019-03-25 Annual: 2018-12-31
10-Q 2018-11-08 Quarter: 2018-09-30
10-Q 2018-08-02 Quarter: 2018-06-30
10-Q 2018-04-27 Quarter: 2018-03-31
10-K 2018-03-23 Annual: 2017-12-31
10-Q 2017-11-09 Quarter: 2017-09-30
10-Q 2017-08-04 Quarter: 2017-06-30
10-Q 2017-05-10 Quarter: 2017-03-31
10-K 2017-03-29 Annual: 2016-12-31
10-Q 2016-11-04 Quarter: 2016-09-30
10-Q 2016-08-10 Quarter: 2016-06-30
10-Q 2016-05-06 Quarter: 2016-03-31
10-K 2016-03-28 Annual: 2015-12-31
10-Q 2015-11-10 Quarter: 2015-09-30
10-Q 2015-08-07 Quarter: 2015-06-30
10-Q 2015-05-13 Quarter: 2015-03-31
10-K 2015-03-27 Annual: 2014-12-31
10-Q 2014-11-12 Quarter: 2014-09-30
10-Q 2014-08-08 Quarter: 2014-06-30
10-Q 2014-05-09 Quarter: 2014-03-31
10-K 2014-03-21 Annual: 2013-12-31
10-Q 2013-11-07 Quarter: 2013-09-30
10-Q 2013-08-05 Quarter: 2013-06-30
10-Q 2013-05-09 Quarter: 2013-03-31
10-K 2013-03-15 Annual: 2012-12-31
10-Q 2012-11-13 Quarter: 2012-09-30
10-Q 2012-08-10 Quarter: 2012-06-30
10-Q 2012-05-10 Quarter: 2012-03-31
10-K 2012-03-29 Annual: 2011-12-31
10-Q 2011-11-10 Quarter: 2011-09-30
10-Q 2011-08-12 Quarter: 2011-06-30
10-Q 2011-05-09 Quarter: 2011-03-31
10-K 2011-03-28 Annual: 2010-12-31
10-Q 2010-11-04 Quarter: 2010-09-30
10-Q 2010-08-10 Quarter: 2010-06-30
10-Q 2010-05-04 Quarter: 2010-03-31
10-K 2010-03-29 Annual: 2009-12-31
8-K 2019-07-31 Enter Agreement, Other Events, Exhibits
8-K 2018-11-30 Sale of Shares, Exhibits
8-K 2018-11-05 Other Events, Exhibits
8-K 2018-08-20 Enter Agreement, Other Events, Exhibits
8-K 2018-08-04 Officers, Other Events, Exhibits

Lixte Biotechnology Holdings Financials

LIXT Metrics, Comps, Filings

Annual | Quarterly

Business

Lixte Biotechnology Holdings, Inc., a Delaware corporation, including its wholly-owned Delaware subsidiary, Lixte Biotechnology, Inc. (collectively, the “Company”), is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Company's product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases.

The Company's activities are subject to significant risks and uncertainties, including the need for additional capital, as described below. The Company has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, and is dependent on periodic infusions of equity capital to fund its operating requirements.

The Company's primary focus is developing new treatments for human cancers for which better therapies are urgently needed. The scope of potential applications of the Company's products has expanded to other common non-malignant diseases, including vascular diseases (heart attacks and stroke, diabetes, genetic diseases, such as Gaucher's disease), and recently to depression and potentially post-traumatic stress syndrome. This has occurred because the targets selected by the Company have multiple functions in the cell, which, when altered, result in different disorders that may benefit by treatment from the Company's products.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Integrity Applications (IGAP) 56,681 0% 5.1 349% 3,055 3,040 136 0 10,648 10,648 54,350
Greenbox Pos (GRBX) 56,573 83% 392.4 3% 750 919 588 489 26 144 56,573
Highlands Bankshares (HBKA) 55,852 1.0 1% 611,721 551,690 0 0 3,690 8,460 8,097
Arch Therapeutics (ARTH) 55,545 -10.2 -136% 3,791 3,962 0 0 -5,155 -5,155 52,363
CTD Holdings (CTDH) 55,443 93% -9.0 -71% 7,591 2,751 958 894 -5,425 -5,425 48,836
Applied Energetics (AERG) 55,133 -16.6 -421% 797 2,151 0 0 -3,352 -3,314 55,033
Sansal Wellness Holdings (SSWH) 54,357 47% -8.6 -50% 12,580 1,172 5,758 2,724 -6,314 -5,986 51,317
Hoth Therapeutics (HOTH) 54,142 -23.8 -47% 4,428 239 0 0 -2,097 -2,097 49,850
Target Group (CBDY) 54,136 -11.6 -21% 21,520 6,926 0 0 -4,597 -4,515 52,358
Lixte Biotechnology Holdings (LIXT) 53,637 -20.7 -67% 3,619 223 0 0 -2,422 -2,422 50,073
Investview (INVU) 53,588 97% -129.0 -8% 11,005 12,301 26,918 25,980 -841 -414 53,485
Victory Oilfield Tech (VYEY) 53,272 46% -2.1 -166% 19,052 3,203 399 184 -31,533 -31,259 64,811
Discovery Energy (DENR) 53,179 6.3 200% 3,159 5,564 0 0 6,325 8,434 53,056
AIT Therapeutics (AITB) 52,586 0% -4.3 -74% 13,120 5,260 627 0 -9,744 -9,619 40,886
Cyberfort Software (CYBF) 51,988 -221.1 -1,194,273% 0 758 0 0 -311 -235 51,988
Skkynet Cloud Systems (SKKY) 51,488 139% -122.7 -45% 924 312 1,039 1,443 -414 -414 50,787
Pacific Health Care Organization (PFHO) 51,264 0% 24.0 12% 9,748 1,103 7,151 0 1,198 1,824 43,711
Farmers & Merchants Bancshares (FMFG) 50,851 4.2 1% 436,449 388,714 0 0 4,768 6,720 28,195
Xspand Products Lab (XSPL) 50,811 32% -21.7 -13% 30,398 17,023 16,094 5,100 -3,840 -2,275 49,436
Consumers Bancorp (CBKM) 50,528 0% 4.2 1% 553,936 502,770 3,226 0 5,566 9,766 41,067

Balance Sheet ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash141,65547544252001,3064,273
Accounts Receivable
Inventory
PP&E
Assets4301,7535585395984331,3684,337
Accounts Payable
Long-Term Debt
Liabilities351261322273286219373211
Stockholders' Equity791,4922362663122159954,126
Income Statement ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue000020000
Cost of Revenue255325
Gross Profit-25147
R&D1,3351,0128801,1182,0921,30146710
SG&A5331,0944951,2857548341,3432,097
Tax00000000
Net Income-2,068-3,579-1,375-2,766-2,852-2,135-1,808-2,133
Cash Flow ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating-1,360-1,206-1,180-1,636-2,181-1,677-1,412-1,511
Cash Investing1,250345-2081101040
Cash Financing52,50201,4122,0521,7482,5184,478